Javascript must be enabled to continue!
Transactivation of PDGFRβ by dopamine D4 receptor does not require PDGFRβ dimerization
View through CrossRef
Abstract
Growth factor-induced receptor dimerization and cross-phosphorylation are hallmarks of signal transduction via receptor tyrosine kinases (RTKs). G protein-coupled receptors (GPCRs) can activate RTKs through a process known as transactivation. The prototypical model of RTK transactivation involves ligand-mediated RTK dimerization and cross-phosphorylation. Here, we show that the platelet-derived growth factor receptor β (PDGFRβ) transactivation by the dopamine receptor D4 (DRD4) is not dependent on ligands for PDGFRβ. Furthermore, when PDGFRβ dimerization is inhibited and receptor phosphorylation is suppressed to near basal levels, the receptor maintains its ability to be transactivated and is still effective in signaling to ERK1/2. Hence, the DRD4-PDGFRβ-ERK1/2 pathway can occur independently of a PDGF-like ligand, PDGFRβ cross-phosphorylation and dimerization, which is distinct from other known forms of transactivation of RTKs by GPCRs.
Springer Science and Business Media LLC
Title: Transactivation of PDGFRβ by dopamine D4 receptor does not require PDGFRβ dimerization
Description:
Abstract
Growth factor-induced receptor dimerization and cross-phosphorylation are hallmarks of signal transduction via receptor tyrosine kinases (RTKs).
G protein-coupled receptors (GPCRs) can activate RTKs through a process known as transactivation.
The prototypical model of RTK transactivation involves ligand-mediated RTK dimerization and cross-phosphorylation.
Here, we show that the platelet-derived growth factor receptor β (PDGFRβ) transactivation by the dopamine receptor D4 (DRD4) is not dependent on ligands for PDGFRβ.
Furthermore, when PDGFRβ dimerization is inhibited and receptor phosphorylation is suppressed to near basal levels, the receptor maintains its ability to be transactivated and is still effective in signaling to ERK1/2.
Hence, the DRD4-PDGFRβ-ERK1/2 pathway can occur independently of a PDGF-like ligand, PDGFRβ cross-phosphorylation and dimerization, which is distinct from other known forms of transactivation of RTKs by GPCRs.
Related Results
Exploring the in vivo subthreshold membrane activity of phasic firing in midbrain dopamine neurons
Exploring the in vivo subthreshold membrane activity of phasic firing in midbrain dopamine neurons
Dopamine is a key neurotransmitter that serves several essential functions in daily behaviors such as locomotion, motivation, stimulus coding, and learning. Disrupted dopamine circ...
Impaired pericyte-Müller glia interaction via PDGFRβ suppression aggravates photoreceptor loss in a rodent model of light-induced retinal injury
Impaired pericyte-Müller glia interaction via PDGFRβ suppression aggravates photoreceptor loss in a rodent model of light-induced retinal injury
AIM: To investigate the involvement of pericyte-Müller glia interaction in retinal damage repair and assess the influence of suppressing the platelet-derived growth factor receptor...
Abstract 1856: Adaptation to dopamine impairs the anti-cancer effect of ONC201 and ONC206
Abstract 1856: Adaptation to dopamine impairs the anti-cancer effect of ONC201 and ONC206
Abstract
ONC201 (originally discovered as TRAIL-Inducing Compound #10 or TIC10) and analogue ONC206 have been found to induce an integrated stress response with sugg...
STIM1 transmembrane helix dimerization captured by AI-guided transition path sampling
STIM1 transmembrane helix dimerization captured by AI-guided transition path sampling
Abstract
STIM1 is a Ca
2+
-sensing protein in the endoplasmic reticulum (ER) membrane. The depletion of ER Ca...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...
Pharmacokinetics of Dopamine in Healthy Male Subjects
Pharmacokinetics of Dopamine in Healthy Male Subjects
Background
Dopamine is an agonist of alpha, beta, and dopaminergic receptors with varying hemodynamic effects depending on the dose of drug being administered. The purp...
Dimerization-based control of cooperativity
Dimerization-based control of cooperativity
Abstract
Cooperativity of ligand–receptor binding influences the input–output behavior of a biochemical system and thus is an important determinant of its physiol...
Chitosan-Catechol Modified Dopamine Sensor
Chitosan-Catechol Modified Dopamine Sensor
Dopamine is a neurotransmitter found in several deep structures of the brain. For example, in the ventral tegmental area (VTA) of the midbrain, in the substantia nigra pars compact...

